摘要
目的探讨肿瘤标志物CYFRA21-1、NSE及CEA联合检测在肺癌早期诊断及肺癌病理类型鉴别中的临床应用价值。方法以本院临床确诊的94例肺癌患者为肺癌组,104例肺部良性病变设为肺良性病变组,同期健康体检68例为对照组,对细胞角蛋白19片段(CYFRA21-1)、神经烯醇化酶(NSE)及癌胚抗原(CEA)联合检测在肺癌的早期诊断进行方法学指标评价,分析不同肺癌病理类型肺癌各种肿瘤标志物的检测情况。结果肺癌组CEA、NSE及CYFRA21-1与对照组及肺良性病变组比较差异均有统计学意义(P<0.05);CEA以腺癌较高,NSE以小细胞癌较高,CYFRA21-1以鳞癌较高;肺癌组中CEA、NSE、CYFRA21-1的阳性率分别为73.4%、36.1%、68.1%,联合检测的阳性率为95.7%,联合检测对各项方法学指标均有不同程度的提升,较为明显的为灵敏度、符合率、约登指数及阴性预测值。结论 3种肿瘤标志的联合检测较适合临床肺癌的筛查。
Objective To explore the clinical value of tumor markers CYFRA21-1, NSE and CEA in the diagnosis of lung cancer and pathological types of lung cancer in early stage. Methods A total of 94 lung cancer patients from our hospital were chosen as lung cancer group, 104 patients as benign lung disease group, and 68 healthy subjects as control group. CYFRA21-1, NSE and CEA joint detection were chosen as evaluation indexes in the early diagnosis of lung cancer. The detection of different tumor markers of different pathological types of lung cancer was analyzed. Resuits CEA, NSE and CYFRA21-1 in lung cancer group and control group and benign lung disease group were statistically different （P 〈 0.05）. CEA in adenocarcinoma was higher, NSE in small cell carcinoma was higher, and CYFRA21-1 in squamous cell carcinoma was higher. In lung cancer group, CEA, NSE and CYFRA21-1 were 73.4%, 36.1%, and 68.1%, respectively. The positive rate of combined detection was 95.7 %. The combined detection improved the sensitive indexes such as sensitivity, accuracy, Youden index and negative predictive value to varying degrees. Conclusion The combined detection of three kinds of tumor markers is more suitable for clinical screening for lung cancer.
出处
《实用临床医药杂志》
CAS
2013年第15期20-22,共3页
Journal of Clinical Medicine in Practice
关键词
肺癌
细胞角蛋白19片段
神经烯醇化酶
癌胚抗原
鳞癌
腺癌
小细胞癌
lung cancer
cytokeratin 19 fragment
neural enolase
carcinoembryonic anti- gen
squamous cell carcinoma
adenocarcinoma
small cell carcinoma
